Cancer Care Ontario | Cancer Care Ontario

29 Results

Guidelines and Advice

Alemtuzumab for the Treatment of T-cell Prolymphocytic Leukemia

Status: Archived
ID: 6-22

Jan 2007

Guidelines and Advice

Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer

Status: Archived
ID: 1-9

Jun 2010

Guidelines and Advice

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

Status: Current
ID: GL END 5-7
Version: 3

Nov 2021

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Aug 2023

Guidelines and Advice

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

Status: Education and Information
ID: 7-12 Version 2
Version: 2

May 2013

Guidelines and Advice

Adjuvant Radiotherapy in Women with Stage I Endometrial Cancer

Status: Archived
ID: 4-10

Aug 2013

Guidelines and Advice

Adjuvant Radiotherapy Post-Prostatectomy in T3 or Margin Positive Prostate Cancer

Status: Archived
ID: 3-17
Version: 3

May 2014

Guidelines and Advice

Accelerated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Status: Archived
ID: 5-6c

Nov 2000

Guidelines and Advice

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Status: In-Review
ID: 3-22
Version: N/A

Apr 2020

Guidelines and Advice

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

Status: Current
ID: GL-7-A-2016-3

Apr 2017

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Aug 2022

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Updated

Mar 2025

Alemtuzumab for the Treatment of T-cell Prolymphocytic Leukemia

Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer

An Endorsement of the 2021 Guideline on Chemotherapy in Combination with Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Altered Fractionation of Radical Radiation Therapy in the Management of Unresectable Non-Small Cell Lung Cancer

Adjuvant Radiotherapy in Women with Stage I Endometrial Cancer

Adjuvant Radiotherapy Post-Prostatectomy in T3 or Margin Positive Prostate Cancer

Accelerated Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Pages